Monday, 25 Sep 2017

You are here

Orencia Approved for Use in Psoriatic Arthritis

On July 6 the U.S. Food and Drug Administration (FDA) approved ORENCIA (abatacept) for the treatment of adults with active Psoriatic Arthritis (PsA). Approval is for both intravenous and subcutaneous (SC) injection formulations. (citation source http://buff.ly/2t6itxn)

This is the third rheumatic disease indication for abatacept (ABA) as it was previously approved for use in rheumatoid arthritis (RA) and moderate to severe polyarticular juvenile idiopathic arthritis and may be used alone or with methotrexate (MTX)

The approval was based on results from two randomized, double-blind, placebo-controlled trials in which abatacept was shown to reduce disease activity in both TNF-naive and previously TNF-exposed PsA patients. The trials  included 594 adult patients. 

The ACR20 response at Week 24  favored ABA over placebo using IV ABA (47.5% versus 19.0% PBO) or SC ABA (39.4% versus 22.3%).  Modest effects on skin scores (compared to other approved agents) were also seen. 

The safety profile seen with PsA patients was as expected with no new safety signals. The approval comes with the warning that abatacept not be administered concomitantly with TNF antagonists, and is not recommended for use concomitantly with other biologics therapies.

Weight based dosing regimens (for both SC and IV forms) is the same as that suggested for RA.  Those receiving the subcutaneous injection once weekly can do so without the need of an intravenous loading dose.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Psoriasis Doubles Mortality Risk

Noe and colleagues have reported in the Journal of Investigative Dermatology that by estimating the extent of skin involvement in psoriasis (%BSA) they may assess future mortality risk. 

Psoriasis patients with 10% or more body surface area (BSA) involvement nearly doubled their risk of early death than those without the disease.

IV Golimumab Shines in Psoriatic Arthritis

Golimumab (GOL) is one of five marketed TNF inhibitors (TNFi) that is FDA approved for use in psoriatic arthritis (PsA). PsA approval was based on a 259 patient, randomized, controlled trial wherein GOL treated patients exhibited at week 24 ACR20/50/70 response of 52%, 32%, and 19%, respectively.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

Psoriatic Arthritis Patients with Comorbidities have Worse Disease and Poor Responses

A population-based cohort study shows that comorbidities in psoriatic arthritis patients (PsA) were associated with higher disease activity, shorter persistence and reduced clinical response to TNF inhibitors (TNFi). 

FDA Arthritis Advisory Panel Endorses Tofacitinib Approval for Psoriatic Arthritis

On Thursday, August 3, the FDA Arthritis Advisory Committee (AAC) met to consider tofacitinib for use in patients with psoriatic arthritis. The panel voted 10-1 in favor of approval.